Losartan for Migraine Prevention
Losartan is not recommended as a first-line agent for migraine prevention, but it may be considered as an alternative option when first-line treatments fail or are not tolerated, particularly in patients with comorbid hypertension. 1
Evidence-Based Positioning
The 2025 American College of Physicians (ACP) guideline explicitly addresses losartan's role in migraine prevention, but notably does not include it among recommended first-line treatments. 1 Instead, the guideline states that ARBs like candesartan and telmisartan (not losartan specifically) should be considered only "if recommended treatments are not tolerated or result in an inadequate response." 1
Key Limitations
Losartan is conspicuously absent from the ACP guideline's discussion of ARBs for migraine prevention—the guideline specifically mentions candesartan and telmisartan, but not losartan. 1
The guideline determined that comparative evidence for ARBs was "inconclusive to inform recommendations" due to limited evidence from studies with small sample sizes and "some" to "high" risk of bias, with no or insufficient comparative effectiveness data. 1
A 2019 systematic review found no randomized controlled trials specifically evaluating losartan for migraine prevention, though other ARBs (candesartan, telmisartan) and ACE inhibitors showed some efficacy. 2
FDA Labeling Perspective
The FDA-approved losartan label does not include migraine prevention as an indication. 3 The approved uses are limited to:
- Hypertension (alone or with other antihypertensives)
- Stroke risk reduction in patients with hypertension and left ventricular hypertrophy
- Slowing diabetic nephropathy progression in type 2 diabetes 3
Interestingly, the FDA label lists "migraine" under adverse reactions in the nervous system disorders category, suggesting migraine as a potential side effect rather than a therapeutic benefit. 3
Clinical Algorithm for ARB Use in Migraine
When to consider ARBs (candesartan or telmisartan, NOT losartan):
First-line treatments have failed after adequate trials (2-3 months) or caused intolerable adverse effects 1
Patient has comorbid hypertension, making an ARB serve dual purposes 2
Cost considerations have been addressed, as ARBs are positioned as alternatives when more established preventives are unsuitable 1
Preferred ARB Selection
If choosing an ARB for migraine prevention:
- Candesartan 16 mg has the strongest evidence, showing superiority to placebo in randomized trials 2
- Telmisartan 80 mg showed high responder rates (>50% reduction in attack frequency) but was not superior to placebo in controlled trials 2
- Losartan lacks specific trial data for migraine prevention and should not be the ARB of choice 2
Practical Implementation
Dosing approach if using an ARB for migraine:
- Start at a low dose and gradually titrate upward 1
- Allow 2-3 months for adequate trial before declaring treatment failure 1
- Effects may become apparent after the first few weeks but continue to improve 1
Important caveats:
- In patients of childbearing potential, discuss teratogenic risks—ARBs can cause fetal harm or death 1, 3
- Monitor for hypotension, hyperkalemia (especially with potassium supplements or potassium-sparing diuretics), and renal function changes 3
- Consider using a headache diary to track efficacy and identify analgesic overuse 1
Bottom Line
If you are specifically considering losartan for migraine prevention, choose a different ARB instead—candesartan has the best evidence. 2 Better yet, ensure first-line migraine preventives (which have stronger evidence) have been adequately tried first, unless the patient has compelling comorbidities like hypertension that make an ARB particularly attractive. 1